| . | Inpatient Participants (n = 542) . | |||||
|---|---|---|---|---|---|---|
| . | Vaccinated SARS-CoV-2 Positive (n = 140)a . | Unvaccinated SARS-CoV-2 Positive (n = 152) . | SARS-CoV-2 Negative (n = 250) . | |||
| Symptoms, % (n)b | ||||||
| Asymptomatic | 1.4 | (2) | 5.3 | (8) | 5.2 | (13) |
| Symptomatic | 75.7 | (106) | 72.4 | (110) | 59.6 | (149) |
| Unable to assess | 22.9 | (32) | 22.4 | (34) | 35.2 | (88) |
| Severity (30 d), % (n)c | ||||||
| SARS-CoV-2 negative | 0.0 | (0) | 0.0 | (0) | 100.0 | (250) |
| Mild | 13.6 | (19) | 9.9 | (15) | 0.0 | (0) |
| Moderate | 65.7 | (92) | 69.7 | (106) | 0.0 | (0) |
| Severe | 14.3 | (20) | 18.4 | (28) | 0.0 | (0) |
| Death | 6.4 | (9) | 2.0 | (3) | 0.0 | (0) |
| Hospitalization duration (60 d), % (n) | ||||||
| 0 | 1.4 | (2) | 1.3 | (2) | 11.2 | (28) |
| 1–2 | 21.4 | (30) | 16.4 | (25) | 27.6 | (69) |
| 3–4 | 20.0 | (28) | 25.7 | (39) | 19.6 | (49) |
| 5–6 | 16.4 | (23) | 18.4 | (28) | 9.6 | (24) |
| 7–8 | 7.9 | (11) | 13.2 | (20) | 10.0 | (25) |
| 9+ | 32.9 | (46) | 25.0 | (38) | 22.0 | (55) |
| Re-hospitalization (60 d), % (n) | ||||||
| Yes | 43.6 | (61) | 30.3 | (46) | 25.2 | (63) |
| . | Inpatient Participants (n = 542) . | |||||
|---|---|---|---|---|---|---|
| . | Vaccinated SARS-CoV-2 Positive (n = 140)a . | Unvaccinated SARS-CoV-2 Positive (n = 152) . | SARS-CoV-2 Negative (n = 250) . | |||
| Symptoms, % (n)b | ||||||
| Asymptomatic | 1.4 | (2) | 5.3 | (8) | 5.2 | (13) |
| Symptomatic | 75.7 | (106) | 72.4 | (110) | 59.6 | (149) |
| Unable to assess | 22.9 | (32) | 22.4 | (34) | 35.2 | (88) |
| Severity (30 d), % (n)c | ||||||
| SARS-CoV-2 negative | 0.0 | (0) | 0.0 | (0) | 100.0 | (250) |
| Mild | 13.6 | (19) | 9.9 | (15) | 0.0 | (0) |
| Moderate | 65.7 | (92) | 69.7 | (106) | 0.0 | (0) |
| Severe | 14.3 | (20) | 18.4 | (28) | 0.0 | (0) |
| Death | 6.4 | (9) | 2.0 | (3) | 0.0 | (0) |
| Hospitalization duration (60 d), % (n) | ||||||
| 0 | 1.4 | (2) | 1.3 | (2) | 11.2 | (28) |
| 1–2 | 21.4 | (30) | 16.4 | (25) | 27.6 | (69) |
| 3–4 | 20.0 | (28) | 25.7 | (39) | 19.6 | (49) |
| 5–6 | 16.4 | (23) | 18.4 | (28) | 9.6 | (24) |
| 7–8 | 7.9 | (11) | 13.2 | (20) | 10.0 | (25) |
| 9+ | 32.9 | (46) | 25.0 | (38) | 22.0 | (55) |
| Re-hospitalization (60 d), % (n) | ||||||
| Yes | 43.6 | (61) | 30.3 | (46) | 25.2 | (63) |
Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Vaccinated participants had completed a primary COVID-19 vaccine series (with or without a booster) ≥14 days before enrollment.
Participants were classified as symptomatic if they indicated ≥1 symptoms on FLU-PRO surveys administered within the first 14 days.
Severity was the maximum illness severity within 30 days. This outcome was only calculated among SARS-CoV-2-positive participants.
| . | Inpatient Participants (n = 542) . | |||||
|---|---|---|---|---|---|---|
| . | Vaccinated SARS-CoV-2 Positive (n = 140)a . | Unvaccinated SARS-CoV-2 Positive (n = 152) . | SARS-CoV-2 Negative (n = 250) . | |||
| Symptoms, % (n)b | ||||||
| Asymptomatic | 1.4 | (2) | 5.3 | (8) | 5.2 | (13) |
| Symptomatic | 75.7 | (106) | 72.4 | (110) | 59.6 | (149) |
| Unable to assess | 22.9 | (32) | 22.4 | (34) | 35.2 | (88) |
| Severity (30 d), % (n)c | ||||||
| SARS-CoV-2 negative | 0.0 | (0) | 0.0 | (0) | 100.0 | (250) |
| Mild | 13.6 | (19) | 9.9 | (15) | 0.0 | (0) |
| Moderate | 65.7 | (92) | 69.7 | (106) | 0.0 | (0) |
| Severe | 14.3 | (20) | 18.4 | (28) | 0.0 | (0) |
| Death | 6.4 | (9) | 2.0 | (3) | 0.0 | (0) |
| Hospitalization duration (60 d), % (n) | ||||||
| 0 | 1.4 | (2) | 1.3 | (2) | 11.2 | (28) |
| 1–2 | 21.4 | (30) | 16.4 | (25) | 27.6 | (69) |
| 3–4 | 20.0 | (28) | 25.7 | (39) | 19.6 | (49) |
| 5–6 | 16.4 | (23) | 18.4 | (28) | 9.6 | (24) |
| 7–8 | 7.9 | (11) | 13.2 | (20) | 10.0 | (25) |
| 9+ | 32.9 | (46) | 25.0 | (38) | 22.0 | (55) |
| Re-hospitalization (60 d), % (n) | ||||||
| Yes | 43.6 | (61) | 30.3 | (46) | 25.2 | (63) |
| . | Inpatient Participants (n = 542) . | |||||
|---|---|---|---|---|---|---|
| . | Vaccinated SARS-CoV-2 Positive (n = 140)a . | Unvaccinated SARS-CoV-2 Positive (n = 152) . | SARS-CoV-2 Negative (n = 250) . | |||
| Symptoms, % (n)b | ||||||
| Asymptomatic | 1.4 | (2) | 5.3 | (8) | 5.2 | (13) |
| Symptomatic | 75.7 | (106) | 72.4 | (110) | 59.6 | (149) |
| Unable to assess | 22.9 | (32) | 22.4 | (34) | 35.2 | (88) |
| Severity (30 d), % (n)c | ||||||
| SARS-CoV-2 negative | 0.0 | (0) | 0.0 | (0) | 100.0 | (250) |
| Mild | 13.6 | (19) | 9.9 | (15) | 0.0 | (0) |
| Moderate | 65.7 | (92) | 69.7 | (106) | 0.0 | (0) |
| Severe | 14.3 | (20) | 18.4 | (28) | 0.0 | (0) |
| Death | 6.4 | (9) | 2.0 | (3) | 0.0 | (0) |
| Hospitalization duration (60 d), % (n) | ||||||
| 0 | 1.4 | (2) | 1.3 | (2) | 11.2 | (28) |
| 1–2 | 21.4 | (30) | 16.4 | (25) | 27.6 | (69) |
| 3–4 | 20.0 | (28) | 25.7 | (39) | 19.6 | (49) |
| 5–6 | 16.4 | (23) | 18.4 | (28) | 9.6 | (24) |
| 7–8 | 7.9 | (11) | 13.2 | (20) | 10.0 | (25) |
| 9+ | 32.9 | (46) | 25.0 | (38) | 22.0 | (55) |
| Re-hospitalization (60 d), % (n) | ||||||
| Yes | 43.6 | (61) | 30.3 | (46) | 25.2 | (63) |
Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Vaccinated participants had completed a primary COVID-19 vaccine series (with or without a booster) ≥14 days before enrollment.
Participants were classified as symptomatic if they indicated ≥1 symptoms on FLU-PRO surveys administered within the first 14 days.
Severity was the maximum illness severity within 30 days. This outcome was only calculated among SARS-CoV-2-positive participants.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
